Q134R: Small chemical compound with NFAT inhibitory properties improves behavioral performance and synapse function in mouse models of amyloid pathology Abstract Inhibition of the protein phosphatase calcineurin (CN) ameliorates pathophysiologic...
Read morePromising new drug candidate can bring a breakthrough in the treatment of Alzheimer’s disease
An interview on the origin and development of our clinical candidate Q134R, on future plans of Aperus Pharma, and on the challenges of treating Alzheimer’s disease is available in the Hungarian online financial jorunal Portfolio. Click here to...
Read moreInterview with the CEO of Aperus Pharma
Interview with the László Puskás, PhD in the hungarian INNOTÉKA magazin. Click here to read the article (hungarian).
Read moreAvidin Publishes in Molecules the Enantioselective Synthesis of 8-Hydroxyquinoline Derivative, Q134 Which is a Hypoxic Adaptation Inducer
Hypoxia is a common feature of neurodegenerative diseases, including Alzheimer’s disease that may be responsible for disease pathogenesis and progression. Therefore, the hypoxia-inducible factor (HIF)1 system, responsible for hypoxic adaptation...
Read moreUnique Drug Candidate Being Developed Against Alzheimer’s Disease Reported by PharmaOnline
The molecule Q134R is believed to be unique in this field. It has three mechanisms of action on important pathways of Alzheimer’s disease at the same time. In the last few years, there have been many developments in antibody or small molecule...
Read moreNew Patent Granted in USA
Enantiomers of lead compounds for neurodegenerative diseases has been granted in the U.S.A. Avidin’s patent, entitled ‘Enantiomers of 8-Hydroxy Quinoline derivatives and the synthesis’ was granted by the US Patent Office under publication number...
Read moreBIO2019 Convention in Philadelphia (PA)
Avidin at BIO International Convention (BIO 2019) – Philadelphia, PA Avidin’s CEO László Puskás and Head of International Relations Klára Kitajka are participating at BIO 2019 to access to global biotech and pharma One-on-One Partnering and...
Read moreAlzheimer’s and Parkinson’s Diseases Congress Lisbon
Avidin presented poster titled “Q134R, a clinical candidate against Alzheimer’s disease with multiple mechanisms of action is a selective GABAA receptor antagonists with cognition improving efficacy “ in collaboration with the Brain Research...
Read more